Unknown

Dataset Information

0

Spironolactone ameliorates endothelial dysfunction through inhibition of the AGE/RAGE axis in a chronic renal failure rat model.


ABSTRACT: BACKGROUND:Spironolactone can improve endothelial dysfunction in the setting of heart failure and diabetes models. However, its beneficial effect in the cardiovascular system is not clear in the setting of non-diabetic renal failure. We conducted this study to investigate whether spironolactone can ameliorate endothelial dysfunction in a 5/6 nephrectomy model, and to determine the underlying mechanism. METHODS:Twenty-four Sprague-Dawley rats were divided into four groups. A renal failure model was created using the 5/6 nephrectomy method. The four groups included: Sham-operation group (Group1), chronic kidney disease (CKD; Group2), CKD?+?ALT-711 (advanced glycation end products [AGEs] breaker; Group 3), and CKD?+?spironolactone group (Group4). Acetylcholine (Ach)-mediated vasodilatation responses were compared between the four groups. To investigate the underlying mechanism, we cultured human aortic endothelial cells (HAECs) for in-vitro assays. Differences between two groups were determined with the paired student's t test. Differences between three or more groups were determined through one-way analysis of variance (ANOVA) with post-hoc analysis with LSD method. RESULTS:Compared with Group 1, Group 2 has a significantly impaired Ach-mediated vasodilatation response. Group 3 and 4 exhibited improved vasoreactivity responses. To determine the underlying mechanism, we performed an in-vitro study using cultured HAECs. We noted significant sirtuin-3 (SIRT3) protein downregulation, reduced phosphorylation of endothelial nitric oxide synthase at serine 1177 (p-eNOS), and increased intracellular oxidative stress in cultured HAECs treated with AGEs (200??g/mL). These effects were counter-regulated when cultured HAECs were pretreated with spironolactone (10??M). Furthermore, the increased p-eNOS production by spironolactone was abrogated when the HAECs were pretreated with tenolvin (1??M), a SIRT3 inhibitor. CONCLUSIONS:Spironolactone could ameliorate endothelial dysfunction in a 5/6 nephrectomy renal failure model through AGEs/Receptor for AGEs (RAGEs) axis inhibition, SIRT3 upregulation, and nicotinamide adenine dinucleotide phosphate oxidase-2 (NOX-2) and its associated intracellular oxidative stress attenuation.

SUBMITTER: Wang CC 

PROVIDER: S-EPMC6729054 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Spironolactone ameliorates endothelial dysfunction through inhibition of the AGE/RAGE axis in a chronic renal failure rat model.

Wang Chun-Cheng CC   Lee An-Sheng AS   Liu Shu-Hui SH   Chang Kuan-Cheng KC   Shen Ming-Yi MY   Chang Chiz-Tzung CT  

BMC nephrology 20190906 1


<h4>Background</h4>Spironolactone can improve endothelial dysfunction in the setting of heart failure and diabetes models. However, its beneficial effect in the cardiovascular system is not clear in the setting of non-diabetic renal failure. We conducted this study to investigate whether spironolactone can ameliorate endothelial dysfunction in a 5/6 nephrectomy model, and to determine the underlying mechanism.<h4>Methods</h4>Twenty-four Sprague-Dawley rats were divided into four groups. A renal  ...[more]

Similar Datasets

| S-EPMC7445400 | biostudies-literature
| S-EPMC5028274 | biostudies-literature
| S-EPMC6685766 | biostudies-literature
| S-EPMC5828936 | biostudies-literature
| S-EPMC6381374 | biostudies-literature
| S-EPMC3359767 | biostudies-literature
| S-EPMC3644255 | biostudies-other
| S-EPMC5562221 | biostudies-literature
| S-EPMC5450936 | biostudies-literature
| S-EPMC8096081 | biostudies-literature